Background/aims: The economic burden for gastroesophageal reflux disease (GERD) has recently increased in Asian countries. This study investigates the cost-effectiveness between anti-reflux surgery and medication, with proton pump inhibitors (PPIs) for GERD in Korea.
Methods: We used a decision tree and Markov model to obtain the costs and quality-adjusted life years (QALYs) of the surgical and medical strategies. Our target cohort was the severe GERD patients aged 50 years old who required a continuous double dose of PPIs. The time horizon was 10 years and all estimates were discounted at 5% per year. The incremental cost-effectiveness ratio of the anti-reflux surgery compared with medication with PPIs was calculated. Sensitivity analyses were performed on all relevant variables.
Results: The cost-utility analysis indicated anti-reflux surgery was more cost-effective than medication among severe GERD patients over a 10-year period. The model predicted that the surgical strategy had a cost savings of $551 and the QALYs had a gain of 1.18 as compared with the medical strategy. The break-even point in costs of the anti-reflux surgery over the medication was estimated to be 9 years. Sensitivity analyses using the varying parameter assumptions demonstrated the robustness of the study results.
Conclusions: This study showed anti-reflux surgery was less expensive and more effective therapy over the PPI medication after 9 years of follow-up. This suggests the surgical strategy is a cost-effective alternative to PPI medication among patients who need long-term management for GERD in Korea.
Keywords: Cost of illness; Gastroesophageal reflux disease; Proton pump inhibitors; Quality-adjusted life years.
Conflict of interest statement
A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.Am J Gastroenterol. 2000 Feb;95(2):395-407. doi: 10.1111/j.1572-0241.2000.01759.x. Am J Gastroenterol. 2000. PMID: 10685741
The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis.Can J Gastroenterol. 2008 Jun;22(6):552-8. doi: 10.1155/2008/765458. Can J Gastroenterol. 2008. PMID: 18560633 Free PMC article.
Treatment Pattern and Economic Burden of Refractory Gastroesophageal Reflux Disease Patients in Korea.J Neurogastroenterol Motil. 2020 Apr 30;26(2):281-288. doi: 10.5056/jnm19050. J Neurogastroenterol Motil. 2020. PMID: 31682754 Free PMC article.
The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2002 Feb;16(2):261-73. doi: 10.1046/j.1365-2036.2002.01167.x. Aliment Pharmacol Ther. 2002. PMID: 11860409 Review.
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. doi: 10.3310/hta11510. Health Technol Assess. 2007. PMID: 18021578 Review.
Cited by 1 article
Cost-effective Management of Severe Gastroesophageal Reflux Disease: Toward an Improved Understanding of Anti-reflux Surgery.J Neurogastroenterol Motil. 2020 Apr 30;26(2):169-170. doi: 10.5056/jnm20025. J Neurogastroenterol Motil. 2020. PMID: 32235025 Free PMC article. No abstract available.